Kenichi Yoshimura - Concepedia

Author

Kenichi Yoshimura

National Cancer Center Hospital East ORCID

Also Known As

Akihiro Kanematsu, Haruhiko Nakayama, Hiroshi Kasanuki, Junya Fukuoka, K YOSHIMURA, K Yoshimura, K. Yoshimura, K., Yoshimura, KENICHI YOSHIMURA, Keisuke Yoshimura

428

Publications

9.6K

Citations

H-Index

178

Concepts

All Affiliations

National Cancer Center Hospital East Hiroshima University Hospital Kyoto University Hospital Kanazawa University Kyoto University

About

Kenichi Yoshimura is an author at National Cancer Center Hospital East specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	70	4.6K
2	Health Sciences	15	18	948
3	Engineering	9	9	528
4	Natural Sciences	2	2	39
5	Education	1	1	21

Kenichi Yoshimura

147

Publications

8.8K

Citations

H-Index

Page 1

	Year	Citations
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Gut	2019	686
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration Rebecka L. Meyers, Rudolf Maibach, Eiso Hiyama, The Lancet Oncology HepatologyPaediatric HepatoblastomaHepatobiliary TumorUnified AnalysisPediatrics	2016	424
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer Masashi Kanai, Kenichi Yoshimura, Masanori Asada, Cancer Chemotherapy and Pharmacology Pancreatic CancerPhase I/ii StudyMedicinePharmacologyGemcitabine-based Chemotherapy	2010	391
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida, American Journal of Kidney Diseases	2018	370
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, The Lancet. Gastroenterology & hepatology HepatologyMedicineClinical TrialsLiver CancerAdvanced Hepatocellular Carcinoma	2018	303
The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model Piotr Czauderna, Beate Haeberle, Eiso Hiyama, European Journal of Cancer HepatologyMedicineHepatobiliary TumorBiliary CancerHistopathology	2015	271
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, Cancer Immunology Research Anti-pd-1 TherapyPd-1 BlockadeT-regulatory CellImmunologyImmune Regulation	2019	255
Risk of Cancer in Patients With Autoimmune Pancreatitis Masahiro Shiokawa, Yuzo Kodama, Kenichi Yoshimura, The American Journal of Gastroenterology	2013	253
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>) Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Journal of Hepato-Biliary-Pancreatic Sciences	2022	226
Pathogenicity of IgG in patients with IgG4-related disease Masahiro Shiokawa, Yuzo Kodama, Katsutoshi Kuriyama, Gut	2016	192

Page 1